These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18458567)

  • 1. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between the 5,10-MTHFR 677C>T and RFC1 80G>A Polymorphisms and Acute Lymphoblastic Leukemia.
    Gómez-Gómez Y; Organista-Nava J; Villanueva-Flores F; Estrada-Brito JS; Rivera-Ramírez AB; Saavedra-Herrera MV; Jiménez-López MA; Illades-Aguiar B; Leyva-Vázquez MA
    Arch Med Res; 2019 May; 50(4):175-180. PubMed ID: 31499477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children.
    Chan JY; Ugrasena DG; Lum DW; Lu Y; Yeoh AE
    Hematol Oncol; 2011 Sep; 29(3):116-23. PubMed ID: 20824655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
    Aplenc R; Thompson J; Han P; La M; Zhao H; Lange B; Rebbeck T
    Cancer Res; 2005 Mar; 65(6):2482-7. PubMed ID: 15781665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.
    Kishi S; Griener J; Cheng C; Das S; Cook EH; Pei D; Hudson M; Rubnitz J; Sandlund JT; Pui CH; Relling MV
    J Clin Oncol; 2003 Aug; 21(16):3084-91. PubMed ID: 12915598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
    Chiusolo P; Reddiconto G; Farina G; Mannocci A; Fiorini A; Palladino M; La Torre G; Fianchi L; Sorà F; Laurenti L; Leone G; Sica S
    Leuk Res; 2007 Dec; 31(12):1669-74. PubMed ID: 17512587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia.
    Zhou Y; He H; Ding L; Wang T; Liu X; Zhang M; Zhang A; Fu J
    Eur J Pediatr; 2024 Feb; 183(2):581-590. PubMed ID: 37851084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association between the methylenetetrahydrofolate reductase gene polymorphisms and haplotype with toxicity response of high dose methotrexate chemotherapy].
    Liao QC; Li XL; Liu ST; Zhang Y; Li TY; Qiu JC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Jul; 33(7):735-9. PubMed ID: 22968027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.
    Karathanasis NV; Stiakaki E; Goulielmos GΝ; Kalmanti M
    Int J Lab Hematol; 2014 Aug; 36(4):425-30. PubMed ID: 24237708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.